glp-1 drugs for parkinson's disease Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine The Emerging Role of GLP-1
Description
Gut microbiome and depression: what we know and what we need to know
Four of these patients (57.1%) experienced at least one AKI episode, and all four experienced recurrent episodes
D., Owens M
North America leads the GLP-1 medications market, generating 77.72% of global revenue for GLP-1 receptor agonists and 75.5% for GLP-1 weight-loss medications in 2024
Current Molecular Pharmacology
CVOTs primarily proved cardiovascular safety and tolerability of different GLP-1 receptor agonists, but also showed cardiovascular benefit of specific drugs
